

# **Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2017**

<https://marketpublishers.com/r/ABF28D1D1BEEN.html>

Date: November 2017

Pages: 44

Price: US\$ 3,500.00 (Single User License)

ID: ABF28D1D1BEEN

## **Abstracts**

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2017

### **SUMMARY**

According to the recently published report 'Acyl CoA Desaturase - Pipeline Review, H2 2017'; Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Stearoyl-CoA desaturase 1 is a protein encoded by the SCD gene. Stearoyl-CoA desaturase-1 plays an important enzyme in fatty acid metabolism. Alteration in SCD1 expression changes the fatty acid profile of these lipids and produces diverse effects on cellular function. High SCD1 expression is correlated with metabolic diseases such as obesity and insulin resistance, whereas low levels are protective against these metabolic disturbances. SCD1 is also involved in the regulation of inflammation and stress in distinct cell types, including  $\beta$ -cells, adipocytes, macrophages, endothelial cells, and myocytes. Complete loss of SCD1 expression has been implicated in liver dysfunction and several inflammatory diseases such as dermatitis, atherosclerosis, and intestinal colitis.

The report 'Acyl CoA Desaturase - Pipeline Review, H2 2017' outlays comprehensive information on the Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics, complete

with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Preclinical, Discovery and Unknown stages are 1, 4, 1 and 1 respectively. Report covers products from therapy areas Gastrointestinal, Metabolic Disorders, Oncology, Dermatology and Infectious Disease which include indications Non-Alcoholic Steatohepatitis (NASH), Acne Vulgaris, Colorectal Cancer, HIV-Associated Lipodystrophy Syndrome, Liver Fibrosis, Metastatic Renal Cell Carcinoma, Non Alcoholic Fatty Liver Disease (NAFLD) and Obesity.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1)

The report reviews Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC

1.14.19.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Overview

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Companies Involved in Therapeutics

Development

Daiichi Sankyo Co Ltd

Galmed Pharmaceuticals Ltd

Johnson & Johnson

Novartis AG

Takeda Pharmaceutical Co Ltd

Thesan Pharmaceuticals Inc

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Drug Profiles

Aramchol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit SCD1 for Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

## R&D Progress

Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity - Drug Profile

Product Description

Mechanism Of Action

## R&D Progress

Small Molecules to Inhibit SCD1 for Metastatic Renal Cell Carcinoma - Drug Profile

Product Description

Mechanism Of Action

## R&D Progress

T-3764518 - Drug Profile

Product Description

Mechanism Of Action

## R&D Progress

TSN-2898 - Drug Profile

Product Description

Mechanism Of Action

## R&D Progress

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Dormant Products

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Discontinued Products

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Product Development Milestones

## Featured News & Press Releases

Nov 07, 2017: Galmed Pharmaceuticals to Provide Corporate Overview at the Stifel 2017 Healthcare Conference

Oct 19, 2017: Galmed Pharmaceuticals to Host Key Opinion Leader Meeting on Non-Alcoholic Steato-Hepatitis (NASH)

Oct 05, 2017: Galmed Pharmaceuticals Announces Publication of Data on Aramchol Mechanism of Action in Hepatology Communications, Data Will Also Be Presented at AASLD

Apr 05, 2017: Galmed Pharmaceuticals to Present at International Liver Congress Data that Shows Aramchol has a Potential Direct Effect on Liver Fibrosis

Jan 09, 2017: Galmed Pharmaceuticals Completes Patient Recruitment for ARREST Phase IIb NASH study

Sep 22, 2016: Galmed Pharmaceuticals and the University of California, San Diego Enter into an Investigator-Initiated Clinical Trial Agreement to Assess Aramchol Effects Juvenile Population

Jun 07, 2016: Galmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study

to China

Jun 01, 2016: Galmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial

Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease

Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study

Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramchol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease

Aug 13, 2015: Galmed Pharmaceuticals Announces the Commencement of Patient Screening in the ARREST Study in the United States and Latin America

Mar 09, 2015: Galmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States

Jan 28, 2015: Galmed and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production

Dec 01, 2014: Galmed Pharmaceuticals Completes Analysis of a Pharmacokinetic Study of Aramchol in Healthy Volunteers

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Pipeline by Galmed Pharmaceuticals Ltd, H2 2017

Pipeline by Johnson & Johnson, H2 2017

Pipeline by Novartis AG, H2 2017

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017

Pipeline by Thesan Pharmaceuticals Inc, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

### COMPANIES MENTIONED

Daiichi Sankyo Co Ltd

Galmed Pharmaceuticals Ltd

Johnson & Johnson

Novartis AG

Takeda Pharmaceutical Co Ltd

Thesan Pharmaceuticals Inc

## I would like to order

Product name: Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2017

Product link: <https://marketpublishers.com/r/ABF28D1D1BEEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ABF28D1D1BEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

